Azione 867 CHINA MEDICAL SYSTEM HOLDINGS LIMITED
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue China Medical System Holdings Limited

Azioni

867

KYG211081248

Mercato chiuso - Hong Kong S.E.
Altri mercati azionari
 10:08:27 12/07/2024 		Variaz. 5gg Var. 1 gen.
6,61 HKD +2,48% Grafico intraday di China Medical System Holdings Limited -1,34% -52,24%
25/06 China Medical System Holdings Limited completa il dosaggio del primo soggetto nello studio ponte di Fase III di Ruxolitinib Crema nella Dermatite Atopica in Cina CI
18/06 China Medical System ottiene il certificato di registrazione del farmaco per la visualizzazione delle lesioni in Cina MT

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!
Registrazione 100% gratuita
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China
China Medical System Holdings Limited Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China
Cosmo's oral diagnostic drug Lumeblue receives approval of New Drug Application in China
Bourse Zurich: séance en manque d'impulsion en perspective
Feu vert pour le bleu de méthylène Lumeblue de Cosmo en Chine
China Medical System Gets Drug Registration Certificate for Lesion Visualization Drug in China
China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China
China Medical System Holdings Limited Announces Approval of Lumeblue® by NMPA for Enhanced Colorectal Lesion Detection
China Medical System Holdings Limited Approves Final Dividend for the Year Ended 31 December 2023
China Medical System: New Drug Application of Desidustat Tablets Accepted in China
China Medical System's Anti-Anaemia NDA Accepted in China
China Medical System Holdings Limited Announces New Drug Application of Desidustat Tablets Accepted in China
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator
China Medical System Registers New Vitiligo Drug in Macau
China Medical System Holdings Limited commences an Equity Buyback for 245,198,851 shares, representing 10% of its issued share capital, under the authorization approved on April 28, 2023.
Incyte, China Medical System Sign Collaboration, License Agreement
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia
Incyte Corporation and China Medical System Holdings Limited Announce Collaboration and License Agreement for Povorcitinib, an Oral Jak1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
China Medical System （867.HK）2023 Annual Results: Despite of the Temporary Financial Performance Pressure Fresh Catalysts Emerged from Successive Innovation Breakthroughs
China Medical System Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione 867
  4. Notizie China Medical System Holdings Limited
  5. Altre lingue